ZY Key Statistics, Chart & Performance
The current stock price of ZY is 2.43 USD. In the past month the price decreased by -6.18%. In the past year, price decreased by -76.75%.
ZY Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ZY. When comparing the yearly performance of all stocks, ZY is a bad performer in the overall market: 73.38% of all stocks are doing better.
ZY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZY. The financial health of ZY is average, but there are quite some concerns on its profitability.
ZY Financial Highlights
Over the last trailing twelve months ZY reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS increased by 53.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2508.94% | ||
| ROA | -77.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ZY Forecast & Estimates
11 analysts have analysed ZY and the average price target is 2.35 USD. This implies a price decrease of -3.46% is expected in the next year compared to the current price of 2.43.
For the next year, analysts expect an EPS growth of 33.88% and a revenue growth -21.93% for ZY
ZY Ownership
About ZY
Company Profile
Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. The company is headquartered in Emeryville, California and currently employs 507 full-time employees. The company went IPO on 2021-04-22. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.
Company Info
ZYMERGEN INC
5959 Horton Street, Suite 700
Emeryville CALIFORNIA US
Employees: 507
Phone: 14158018073.0
ZYMERGEN INC / ZY FAQ
What does ZY do?
Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. The company is headquartered in Emeryville, California and currently employs 507 full-time employees. The company went IPO on 2021-04-22. Its platform consists of three key capabilities: its collection of accessible biomolecules; its software and data science technology, and its data-driven microbe optimization processes. Its businesses include advanced materials, which seeks to employ bio-advantaged molecules or microbes to develop and deliver products and is focused on four markets: agriculture, water repellency, advanced polymers, and healthcare; drug discovery business leverages its differentiated access to natural products as a source of diverse chemical matter provided by its unified metagenomics database, and automation business, which offers automation technology to organizations involved in lab operations. Its software and data science platform informs, guides, and records its experiments forming the infrastructure for the learning cycle.
What is the current price of ZY stock?
The current stock price of ZY is 2.43 USD. The price increased by 1.67% in the last trading session.
What is the dividend status of ZYMERGEN INC?
ZY does not pay a dividend.
How is the ChartMill rating for ZYMERGEN INC?
ZY has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ZY stock?
ZYMERGEN INC (ZY) operates in the Materials sector and the Chemicals industry.
What is the next earnings date for ZY stock?
ZYMERGEN INC (ZY) will report earnings on 2022-11-11, after the market close.